Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Iradimed Q3 2026 Results: Net Income $6.51M, Up 16.7% YoY

For the nine months ended September 30, 2026, IRADIMED reported revenue of $66.6 million, a 9% increase over the prior year period. Net cash and cash equivalents grew to $63.3 million, while total stockholders' equity increased to $106.5 million from $94.6 million at the end of 2025.

Watch the Iradimed Corp earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue24.221.2
Gross profit18.516.5
Profit before tax8.77.3
Net income6.55.6
EPS (diluted, $ a share)$0.51$0.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+16.7%
Revenue, year on year+14.2%
Gross margin76.3%
Operating margin33.6%
Source

10-Q filed with the SEC, NASDAQ: IRMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Iradimed Corp: key numbers

Share price
$84.84Close, Nov 16
Market cap
$1.08B
Shares outstanding
12.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Iradimed Corp

All →
8:37 AM ET 8-K
Financial Results

Iradimed Financial Results

IRADIMED reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase driven by the launch of its new 3870 MR IV pump. The company also declared a quarterly cash dividend of $0.20 per share and updated its full-year 2026 revenue guidance to a range of $91.6 million to $93.1 million.

Term
Q3 2026

“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected.”

Roger Susi, President and Chief Executive Officer of Iradimed

“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61.”

Roger Susi, President and Chief Executive Officer of Iradimed

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.